[Form 4/A] BridgeBio Pharma, Inc. Amended Insider Trading Activity

Rhea-AI Filing Summary

EnerSys (ENS) Form 4 filing: Director Rudolph W. Wynter reported automatic grants of dividend-equivalent equity units on 27 June 2025. The transactions comprise 20.7943 vested Deferred Stock Units (DSUs) and 11.0929 vested Restricted Stock Units (RSUs), plus 0.4726 unvested RSUs spread across four prior award dates. All units were issued at $0.00 cost as part of the company’s cash-dividend adjustment mechanism for non-employee directors. Following the issuances, Wynter’s direct beneficial ownership increased to 11,527.3249 common shares.

The filing reflects routine dividend-equivalent adjustments rather than discretionary purchases or sales, and does not involve any derivative securities. No changes to board roles or compensation terms were disclosed.

Insights

Securities Analyst

TL;DR: Routine dividend-equivalent RSU/DSU credits; immaterial ownership change, neutral impact.

The Form 4 shows typical dividend-equivalent grants under EnerSys’s non-employee director plan. Fewer than 32 shares were added, raising Wynter’s stake by roughly 0.28%. Because the units were issued at no cost and do not signal open-market sentiment, the event carries no valuation impact. It confirms standard board compensation mechanics and signals continued alignment via equity, but offers limited insight into corporate outlook.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valantine Hannah

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/29/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)
01/03/2022

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/29/2021		P		1,752	A	$14.24	3,294	D
Common Stock								2,687	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Hannah A. Valantine, M.D.	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many EnerSys shares did Director Rudolph W. Wynter acquire on 27-Jun-2025?

He received 31.8863 additional shares in the form of dividend-equivalent DSUs and RSUs.

What is Rudolph W. Wynter’s total EnerSys ownership after this Form 4 filing?

His direct beneficial ownership stands at 11,527.3249 common shares.

Were any EnerSys shares purchased on the open market?

No. All units were granted at $0.00 as dividend equivalents; no cash purchases occurred.

Does this filing indicate insider sentiment at EnerSys (ENS)?

The credits are automatic plan adjustments, so they do not reflect discretionary buying or selling intent.

Are derivative securities involved in this Form 4?

No derivative securities were acquired or disposed; only common-stock units were reported.